Author

Yurong Wang

Observed name: Wang, Yurong

Institutions: Nanjing Drum Tower Hospital, Nanjing University

Observed institutions: Nankai University, Chinese PLA General Hospital, Zhengzhou University, Nanjing Drum Tower Hospital, First Affiliated Hospital of Zhengzhou University, Chinese People's Liberation Army, State Key Laboratory of Kidney Diseases, Nanjing University

ORCID: 0000-0002-1025-0631

Observed ORCID: 0000-0002-1025-0631

OpenAlex ID: A5086295803

Serum exosomal micro RNA s combined with alpha‐fetoprotein as diagnostic markers of hepatocellular carcinoma

2018 · Yurong Wang, Chunyan Zhang, et al. · Cancer Medicine · 146

Alectinib versus crizotinib in ALK ‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

2022 · Yurong Wang, Shujing Shen, et al. · Cancer Medicine · 17

SLC9A5 promotes tumor growth and cell motility via ACOX1-mediated peroxisomal fatty acid oxidation

2023 · Ruipan Zheng, Yurong Wang · Experimental Cell Research · 12

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis

2025 · Junren Lu, Daming Cai, et al. · npj Precision Oncology · 2

Aging modulation of the immune system and immunotherapy efficacy in cancer

2026 · Yurong Wang, Mengjie Liang, et al. · Frontiers in Immunology · 1

Works count: 9

Citation count: 178

H-index: 3

I10-index: 3